---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-111665"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-09-29T13:15:22+00:00"
generated_at: "2026-10-12T13:44:12.721038+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma regains Nasdaq minimum bid price compliance after 1-for-50 reverse split

## Summary
- Nasdaq notice dated Sept 24, 2026: closing bid price was above $1.00 for 13 consecutive trading days from Aug 21 to Sept 9, 2026; the matter is now closed.
- Company effected a 1-for-50 reverse stock split at the close of trading on Aug 20, 2026 to cure the bid price deficiency.
- Original Jan 15, 2026 notice: bid below $1.00 for 30 consecutive business days, failing Nasdaq Listing Rule 5450(a)(1) for the Global Market.
- Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective Aug 4, 2026 and set a Sept 3, 2026 deadline under Rule 5550(a)(2).

## SEC filing metadata
- accession: 0001104659-26-111665
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-09-29T13:15:22+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/0001104659-26-111665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-111665
- JSON: https://secwatch.observer/filing/0001104659-26-111665.json
- Plain text: https://secwatch.observer/filing/0001104659-26-111665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.